Advertisement
U.S. markets open in 1 hour 52 minutes

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
128.42+2.06 (+1.63%)
At close: 04:00PM EST
130.24 +1.82 (+1.42%)
Pre-Market: 07:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close126.36
Open126.21
Bid107.99 x 900
Ask141.08 x 800
Day's Range125.57 - 128.47
52 Week Range111.25 - 147.98
Volume294,860
Avg. Volume585,973
Market Cap8.085B
Beta (5Y Monthly)0.62
PE Ratio (TTM)154.72
EPS (TTM)0.83
Earnings DateFeb 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est188.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-7% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Jazz Pharmaceuticals plc
    JAZZ: Lowering target price to $128.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of HOLD; a target price of $128.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • The Wall Street Journal

    Jazz Pharmaceuticals Names Eli Lilly’s Philip Johnson as Next CFO

    Jazz Pharmaceuticals has hired Philip Johnson as executive vice president and chief financial officer, effective March 1. Jazz on Wednesday said Johnson was most recently group vice president of finance at Eli Lilly leading the drugmaker’s treasury and investor-relations operations. Dublin-based biopharmaceutical company Jazz said Johnson, 59 years old, will receive an annual base salary of $700,000, a signing bonus of $150,000 and an annual bonus with a target of 65% of his base pay.

  • PR Newswire

    Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.

  • PR Newswire

    Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: